ASCO GI 2021 | Phase I study of OBP-301 for locally advanced esophageal cancer

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the rationale of an ongoing NRG Oncology NRG-GI007 Phase I study of telomelysin and chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery. Telomelysin is a conditionally-restricted, replication-competent adenovirus that adds a hTERT gene promoter, replicating only in tumor cells to cause lysis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).